Search
FDA approves topical treatment addressing repigmentation in vitiligo in patients aged 12 and older
… Action FDA has approved Opzelura (ruxolitinib) cream for the treatment of nonsegmental vitiligo in adult and pediatric patients 12 years of age and … Drug Evaluation and Research … FDA has approved Opzelura (ruxolitinib) cream for the treatment of nonsegmental vitiligo …
Notable Approvals | Drugs
… approves topical treatment addressing repigmentation in vitiligo in patients aged 12 and older 7/19/2022 Opzelura ruxolitinib FDA approves treatment for chronic weight …
jakafi_ruxolitinib_phosphate_and_opzelura_ruxolitinib_pediatric_postmarketing_pharmacovigilance_review.pdf
… Labeling Applicant Type/Number Approval Date Jakafi (ruxolitinib) NDA 202192 12/06/2017 Incyte Corporation tablet 12/19/2022 Opzelura (ruxolitinib) NDA 215309 09/21/2021 Incyte Corporation cream … advisable, and (2) the topical treatment of nonsegmental vitiligo in adult and pediatric patients 12 years of age and …
New Drug Therapy Approvals 2022
… treatment for neoadjuvant lung cancer. Opzelura (ruxolitinib) cream was first approved in 2021 for atopic … In 2022, CDER approved the drug to treat nonsegmental vitiligo, a condition that involves loss of skin coloring in …
215309s1 ruxolitinib multidisciplinary prea
… NDA 215309/S‐001 Opzelura (ruxolitinib) cream, 1.5% NDA/BLA Multi‐Disciplinary Review … Completion Date 18 July 2022 Established/Proper Name Ruxolitinib Trade Name Opzelura Pharmacologic Class Janus … OPZELURA is indicated for the topical treatment of vitiligo in patients 12 years of age and older Applicant …
Curriculum Vitae Seemal R. Desai, M.D., FAAD CV
… Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Foll wed by an Extension Period in Participants with Vitiligo Incyte November 2020 - Present Protocol INCB … Study to Assess the Long-Term Efficacy and Safety of Ruxolitinib Cream in Patticpants with Vitiligo 9 Bibliography …
June 16, 2023 Summary of Safety and Effectiveness Data (SSED) - RECELL Autologous Cell Harvesting Device (Model Number AVRL0102)
… skin processor for preparing cell suspension, for stable vitiligo, with applicator Device Trade Name: RECELL® … is indicated for repigmentation of stable depigmented vitiligo lesions in patients 18 years of age and older. The … System (cleared under K170489). Additionally, Opzelura (ruxolitinib) cream (1.5%) was approved for the topical …